Victoria Creamer Sells 4,179 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Key Points

• Executive Vice President Victoria Creamer sold 4,179 CRL shares at an average price of $259.16, generating approximately $1.08 million and reducing her holdings by 12.21% to 30,051 shares.
• Charles River Laboratories reported quarterly EPS of $3.02, beating estimates of $2.77, while revenue reached $1 billion; however, revenue declined 2.7% year over year and the company posted a negative net margin.
• Analysts remain broadly bullish, with 12 Buy ratings and a consensus “Moderate Buy” assessment; several firms raised their price targets to between $282 and $310 as CRL shares climbed 3.3% to $276.34.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Victoria Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares of the company's stock, valued at $7,788,017.16. This represents a 12.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Charles River Laboratories International Stock Up 3.3%

Shares of NYSE:CRL traded up $8.85 during trading hours on Monday, reaching $276.34. The stock had a trading volume of 1,025,309 shares, compared to its average volume of 924,952. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $277.07. The firm's 50 day moving average is $214.85 and its 200-day moving average is $189.04. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The stock has a market capitalization of $13.19 billion, a price-to-earnings ratio of -56.98, a P/E/G ratio of 2.77 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company's revenue was down 2.7% on a year-over-year basis. During the same period last year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CRL shares. JPMorgan Chase & Co. raised Charles River Laboratories International from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $180.00 to $310.00 in a research report on Thursday. Royal Bank Of Canada boosted their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an "outperform" rating in a research note on Thursday. TD Cowen upped their price target on Charles River Laboratories International from $235.00 to $300.00 and gave the company a "buy" rating in a report on Monday. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research note on Monday. Finally, Evercore restated an "outperform" rating on shares of Charles River Laboratories International in a research report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $255.65.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors have recently modified their holdings of CRL. Invesco Ltd. raised its stake in shares of Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company's stock worth $537,828,000 after purchasing an additional 1,446,972 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Charles River Laboratories International in the 4th quarter valued at $176,478,000. Victory Capital Management Inc. grew its position in Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company's stock valued at $137,935,000 after buying an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company's stock valued at $96,005,000 after buying an additional 575,039 shares during the period. Finally, Amundi raised its position in Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after buying an additional 492,301 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source